Antibody-Based Therapies

The Antibody-Based Therapies program showcases how emerging modalities are reshaping the therapeutic landscape across oncology, autoimmunity, and beyond. From clinical-stage candidates to next-generation immunomodulatory formats, speakers will highlight advances in Fc engineering, receptor agonism, and precision depletion of pathogenic cells. The agenda further explores radiopharmaceuticals, novel scaffolds such as DARPins and affibodies, and targeted protein degradation platforms that expand antibody function into new therapeutic spaces. Together, these sessions provide a forward-looking view of how innovative antibody-based designs are driving more precise and potent therapies for patients.